Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China

Xinyue Yang, BS; Chao Hou, BS; Ye Shen, MS; Mingyang Zhang, MS; Kejun Zhang, MS; Fang Wang, BS; Yuhui Liu, MD; Xiangyu Ma, MD; Lixia Cheng, MS; Jun Kang, BS; Baoman Hu, BS; Man Wang, BS; Ling Zeng, MD; Yanjiang Wang, MD; Yong He, MD; Guoqiang Cao, MD; Jianxin Jiang, MD; Paul Jones, MD; Bin Cao, MD; Li Li, MD

Abstract

IMPORTANCE Relatively little is known about the persistence of symptoms in patients with COVID-19 for more than 1 year after their acute illness.

OBJECTIVE To assess the health outcomes among hospitalized COVID-19 survivors over 2 years and to identify factors associated with increased risk of persistent symptoms.

DESIGN, SETTING, AND PARTICIPANTS This was a longitudinal cohort study of patients who survived COVID-19 at 2 COVID-19–designated hospitals in Wuhan, China, from February 12 to April 10, 2020. All patients were interviewed via telephone at 1 year and 2 years after discharge. The 2-year follow-up study was conducted from March 1 to April 6, 2022. Statistical analysis was conducted from April 20 to May 5, 2022. The severity of disease was defined by World Health Organization guideline for COVID-19.

EXPOSURES COVID-19.

MAIN OUTCOMES AND MEASURES The main outcome was symptom changes over 2 years after hospital discharge. All patients completed a symptom questionnaire for evaluation of symptoms, along with a chronic obstructive pulmonary disease assessment test (CAT) at 1-year and 2-year follow-up visits.

RESULTS Of 3988 COVID-19 survivors, a total of 1864 patients (median [IQR] age, 58.5 [49.0-68.0] years; 926 male patients [49.7%]) were available for both 1-year and 2-year follow-up visits. The median (IQR) time from discharge to follow-up at 2 years was 730 (719-743) days. At 2 years after hospital discharge, 370 patients (19.8%) still had symptoms, including 224 (12.0%) with persisting symptoms and 146 (7.8%) with new-onset or worsening of symptoms. The most common symptoms were fatigue, chest tightness, anxiety, dyspnea, and myalgia. Most symptoms resolved over time, but the incidence of dyspnea showed no significant change (1-year vs 2-year, 2.6% [49 patients] vs 2.0% [37 patients]). A total of 116 patients (6.2%) had CAT total scores of at least 10 at 2 years after discharge. Patients who had been admitted to the intensive care unit had higher risks of persistent symptoms (odds ratio, 2.69; 95% CI, 1.02-7.06; \(P = .04\)) and CAT scores of 10 or higher (odds ratio, 2.83; 95% CI, 1.21-6.66; \(P = .02\)).

CONCLUSIONS AND RELEVANCE In this cohort study, 2 years after hospital discharge, COVID-19 survivors had a progressive decrease in their symptom burden, but those with severe disease during hospitalization, especially those who required intensive care unit admission, had higher risks of persistent symptoms. These results are related to the original strain of the virus, and their relevance to infections with the Omicron variant is not known.

JAMA Network Open. 2022;5(9):e2231790. doi:10.1001/jamanetworkopen.2022.31790

Key Points

Question What are the 2-year health outcomes among patients hospitalized for COVID-19 in China?

Findings In this longitudinal cohort study that included 1864 patients, the most common symptoms at 2 years after SARS-CoV-2 infection were fatigue, chest tightness, anxiety, dyspnea, and myalgia, and most symptoms resolved from 1-year to 2-year follow-up, although the incidence of dyspnea showed no significant change. Patients with severe disease during hospitalization, especially those who required intensive care unit admission, had higher risks of persistent symptoms and higher chronic obstructive pulmonary disease assessment test scores.

Meaning These findings suggest that prolonged symptoms may persist in a proportion of COVID-19 survivors for 2 years after SARS-CoV-2 infection.
Introduction

By May 6, 2022, the global pandemic of COVID-19 had resulted in more than 500 million confirmed cases and 6.1 million deaths.1 With the emergence of new SARS-CoV-2 variants of higher transmissibility (eg, Omicron and Delta), the number of confirmed cases constantly increases.2,3 Although most SARS-CoV-2-infected patients recover from the acute phase, some patients may experience long-lasting health problems, including physical, cognitive, and psychological sequelae, affecting their social participation and health-related quality of life.4-6 Therefore, systematic follow-up of patients with COVID-19 discharged from the hospital is necessary to identify the trajectory of symptom burden, to understand the long-term health outcomes of this disease.

Previous studies7-10 have indicated that a substantial proportion of COVID-19 survivors still experience problems in various health domains after hospital discharge. In a large national cohort7 of people with COVID-19 and contemporary and historical controls, an increased risk of incident mental health disorders (eg, anxiety disorders and depressive disorders) was found in people with COVID-19 compared with those with seasonal influenza. In an exploratory prospective cohort study8 involving patients who survived 1 year following intensive care unit (ICU) treatment for COVID-19, physical, mental, or cognitive symptoms were frequently reported. We previously reported9 that in a cohort of 2433 hospitalized COVID-19 survivors, 45.0% of patients reported at least 1 symptom 1 year after hospital discharge, and patients with severe disease had increased risk of having more symptoms. However, whether COVID-19–related symptoms may persist for a longer time is still in question. Most recently, a longitudinal follow-up study10 described the evolution of health and functional outcomes among COVID-19 survivors up to 2 years and found that health-related quality of life, exercise capacity, and mental health continued to improve throughout the 2 years regardless of initial disease severity. In the current study, we investigated the dynamic trajectory of symptom burden and symptom persistence of COVID-19 survivors 2 years after discharge from 2 designated hospitals.

Methods

This study was approved by the Ethics Committee of the Daping Hospital, Army Medical University, since its medical staff worked in the COVID-19–designated Huoshenshan Hospital and Taikang Tongji Hospital during the acute phase of the pandemic in early 2020. Verbal informed consent was obtained from COVID-19 survivors or their legal guardians before the study. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline was implemented.

Study Design and Patients

This is a longitudinal cohort study involving COVID-19 survivors who were discharged from Huoshenshan Hospital and Taikang Tongji Hospital (both in Wuhan, China) between February 12 and April 10, 2020. All adult patients with laboratory-confirmed COVID-19 were screened for eligibility. The exclusion criteria included (1) those who declined to participate, (2) those unable to be contacted, and (3) those who died before the follow-up. The 2-year follow-up study was conducted from March 1 to April 6, 2022.

Procedures

All patients were contacted in the order of their discharge date documented in their medical record. At each follow-up, patients underwent a standardized telephone interview and completed a self-reported symptom questionnaire and a chronic obstructive pulmonary disease (COPD) assessment test (CAT), which was initially designed to assess symptom burden of patients with COPD based on a modeling study of the association between CAT scores and impact of COPD on daily life and well-being.11-13 The questionnaire at 1-year follow-up was based on symptoms that had been reported by patients during hospitalization and was described in an earlier study.9 The questionnaire at 2-year
follow-up was based on symptoms that had been reported at 1-year follow-up, as shown in eTable 1 in the Supplement. The symptoms included in the study questionnaire were graded according to a 4-point Likert scale (no problems, mild problems, moderate problems, or severe problems). Symptoms were present if at least 1 problem was rated as moderate or severe. COVID-19 survivors with long COVID-19 symptoms were defined as having at least 1 persistent or new-onset symptom related to COVID-19 that could not be explained by an alternative disease, which is consistent with the case definition of post–COVID-19 condition.14 For patients not responding to the telephone interview for the first time, another 2 attempts were made. On the basis of the dynamic changes of symptom number between years 1 and 2, patients were classified into 4 categories: (1) patients with at least 1 symptom at both follow-up time points were defined as having symptoms persist; (2) patients with at least 1 symptom at 1-year follow-up without symptoms at 2-year follow-up were defined as having symptom relief; (3) patients without any symptom at 1-year follow-up but with at least 1 symptom at 2-year follow-up were defined as having new-onset symptoms, which included patients who had a symptom that was reported as a mild problem at year 1, but at 2-year follow-up was reported as moderate or severe problem; and (4) patients with no symptoms at all at both follow-up time points were defined as having no symptoms.

Data Acquisition
Collection of clinical data during hospitalization of enrolled patients has been described in our previous study of 1-year follow-up.9 Briefly, demographic characteristics (self-reported age, sex, and cigarette smoking) and clinical characteristics (comorbidities and symptoms) were retrieved from electronic medical records. The severity of disease was defined by World Health Organization guideline for COVID-19.9 Patients with severe disease were those with fever or suspected respiratory infection, plus 1 of the following conditions: respiratory rate greater than 30 breaths per minute, severe respiratory distress, or oxygen saturation as measured by pulse oximetry less than or equal to 93% on room air. We double-entered and validated all data using EpiData software version 3.1 (EpiData Association).

Statistical Analysis
Continuous variables were presented as median (IQR), followed by Mann-Whitney U test, and categorical variables were presented as absolute values along with percentages, followed by the Pearson χ² test or Fisher exact test when appropriate. To test the risk of bias due to patients lost to follow-up, the clinical characteristics between the enrolled patients and those lost to follow-up were compared. As an exploratory analysis, a 1:1 propensity score–matching (PSM) was further applied between these 2 subpopulations, based on age, sex, disease severity, and coexisting disorders. To identify factors associated with the risk of occurrence of at least 2 symptoms at 2-year follow-up, symptoms persisting or new-onset symptoms during follow-up, and CAT scores of at least 10, univariable logistic regression analysis was used to identify potential risk factors with P < .10, and then was adjusted by a stepwise (forward likelihood ratio) selection process in multivariable logistic regression model, whereas age, sex, and disease severity were forced into the model because of their importance. All tests were 2-sided, and P < .05 was considered significant. All statistical analyses were performed with the use of SPSS statistical package version 26.0 for Windows (IBM SPSS Statistics) and R statistical software version 4.1.1 (R Project for Statistical Computing) from April 20 to May 5, 2022.

Results
Patient Characteristics
Of 3988 COVID-19 survivors screened for eligibility, a total of 1864 patients (47.0%) who were available for both interviews were included in the final analysis; their median (IQR) age was 58.5 (49.0-68.0) years, and 926 (49.7%) were male (Figure 1). In total, 505 patients (27.1%) were
categorized as having severe disease. The median (IQR) time from discharge to follow-up was 364 (357-371) days at 1 year and 730 (719-743) days at 2 years. The median (IQR) duration of hospital stay was 14 (9-20) days. During hospitalization, 1341 patients (71.9%) received oxygen therapy, among whom 14 patients (0.8%) received mechanical ventilation, and 36 patients (1.9%) were admitted to the ICU. Compared with enrolled patients, the 2124 patients lost to follow-up were older, had more coexisting disorders, including cerebrovascular diseases, hypertension, cardiovascular disease, chronic kidney diseases, and COPD, and had a higher percentage of ICU admission and mechanical ventilation. No significant difference was found in terms of sex, disease severity, the percentage of smokers, or symptoms during hospitalization (Table 1 and eTable 2 in the Supplement). Moreover, no differences in clinical characteristics or 1-year symptoms were seen between the enrolled patients and those lost to follow-up between the 1-year and 2-year interviews (eTable 3 and eTable 4 in the Supplement).

**Characteristics of Long-term Symptoms at 1-Year and 2-Year Follow-up**

During hospitalization, 1777 patients (95.3%) were found with at least 1 COVID-19–related symptom. During follow-up, the proportion of patients with long COVID-19 symptoms constantly decreased (1-year vs 2-year, 43.2% [806 patients] vs 19.8% [370 patients]; difference, 23.4%; 95% CI, 20.5%-26.3%; P < .001). The decrease was seen in patients with severe and nonsevere disease and was numerically greater in those with severe disease (severe disease, 1-year vs 2-year, 52.3% [264 patients] vs 24.4% [123 patients]; difference, 27.9%; 95% CI, 22.2%-33.7%; P < .001; nonsevere disease, 1-year vs 2-year, 39.9% [542 patients] vs 18.2% [247 patients]; difference, 21.7%; 95% CI, 18.4%-25.0%; P < .001). Of those with symptoms at 2-year follow-up, 228 patients (12.2%) reported 1 symptom, 83 (4.5%) reported 2 symptoms, and 59 (3.2%) reported 3 or more symptoms (eFigure 1 in the Supplement).

At 1 year after discharge, the most common symptoms among COVID-19 survivors were fatigue, sweating, chest tightness, anxiety, and myalgia, whereas at 2-year follow-up, the most common symptoms were fatigue, chest tightness, anxiety, dyspnea, and myalgia (Figure 2A; full details are shown in eTable 5 in the Supplement). Fatigue was the most commonly reported symptom at both interviews, whereas the proportion decreased from 26.9% (501 of 1864 patients) at 1-year follow-up to 10.3% (192 of 1864 patients) at 2-year follow-up. Most other symptoms also significantly resolved over time, yet a small percentage of patients reported dyspnea and it showed no significant change (1-year vs 2-year, 2.6% [49 patients] vs 2.0% [37 patients]).

**Figure 1. Study Flowchart**

- **4086** Hospitalized patients with COVID-19
- **3988** Discharged patients
- **2433** Included in 12-mo follow-up study
  - Symptoms assessed by a self-reported questionnaire
  - Symptom burden assessed by CAT scoring
- **1864** Included in 24-mo follow-up study
  - Symptoms assessed by a self-reported questionnaire
  - Symptom burden assessed by CAT scoring
- **98** Died during hospitalization
- **1555** Excluded
  - **796** Declined to participate
  - **759** Unable to be contacted
- **569** Excluded
  - **499** Declined to participate
  - **49** Unable to be contacted
  - **21** Deceased

CAT indicates chronic obstructive pulmonary disease assessment test.
After PSM, 1691 patients (90.7%) in the enrolled population were matched successfully with those lost to follow-up, and the baseline characteristics were comparable (eTable 6 in the Supplement). In the PSM population, the most common symptoms at 2-year follow-up were fatigue (178 patients [10.5%]), anxiety (74 patients [4.4%]), chest tightness (47 patients [2.8%]), dyspnea (35 patients [2.1%]), and myalgia (32 patients [1.9%]), which were similar to those for the overall enrolled population (eTable 7 and eTable 8 in the Supplement).

**Dynamic Trajectory of Symptoms During 2-Year Follow-up**

Regarding the symptom dynamics over 2 years, 224 patients (12.0%) were classified as having symptom persist, 582 (31.2%) as experiencing symptom relief, 146 (7.8%) as having new-onset symptoms, and 912 (48.9%) as having no symptoms (Table 2). Patients with severe disease were more likely to be classified as having symptoms persist (severe vs nonsevere, 17.6% [89 patients] vs 9.9% [135 patients] at 2-year follow-up) and were less likely to be classified as having no symptoms (severe vs nonsevere, 41.0% [207 patients] vs 51.9% [705 patients]). Similarly, in the PSM population, patients with severe disease were more likely to be classified as having symptoms persist, whereas patients with nonsevere disease were more likely to be classified as having no symptoms (eTable 9 in the Supplement). Fatigue, anxiety, chest tightness, dyspnea, and myalgia were the most common symptoms in the symptoms persist group. On the other hand, the most

| Characteristic | Patients, No. (%) | Severe disease (n = 505) | Nonsevere disease (n = 1359) | Lost to follow-up (n = 2124) | P value* |
|---------------|------------------|-------------------------|---------------------------|---------------------------|---------|
|              | Enrolled (n = 1864) |                          |                          |                          |         |
| Age, median (IQR), y | 58.5 (49.0–68.0) | 64.0 (55.0–71.0) | 57.0 (46.0–66.0) | 63.0 (52.0–71.0) | <.001b |
| Sex | Male | 926 (49.7) | 270 (53.3) | 656 (48.3) | 1054 (49.6) | .97 |
| | Female | 938 (50.3) | 235 (46.5) | 703 (51.7) | 1070 (50.4) | .05 |
| Severe disease | 505 (27.1) | NA | NA | 635 (29.9) | .05 |
| Cigarette smoking | Never | 1711 (91.8) | 468 (92.3) | 1243 (91.5) | 1969 (92.7) | .46 |
| | Former | 33 (1.8) | 8 (1.6) | 25 (1.8) | 29 (1.4) | .70 |
| | Active | 120 (6.4) | 29 (5.7) | 91 (6.7) | 126 (5.9) | |
| Coexisting disorders, No. | 0 | 1072 (57.5) | 229 (45.3) | 822 (62.1) | 1073 (50.5) | <.001 |
| | 1 | 464 (24.9) | 140 (27.7) | 313 (23.7) | 589 (27.7) | <.001 |
| | ≥2 | 328 (17.6) | 136 (27.0) | 188 (14.2) | 462 (21.8) | |
| Type of coexisting disorder | Hypertension | 544 (29.2) | 206 (40.8) | 338 (24.9) | 696 (32.8) | .02 |
| | Diabetes | 259 (13.9) | 99 (19.6) | 160 (11.8) | 308 (14.5) | .58 |
| | Cardiovascular diseases | 164 (8.8) | 67 (13.3) | 97 (7.1) | 247 (11.6) | .003 |
| | Chronic liver disease | 96 (5.2) | 24 (4.8) | 72 (5.3) | 116 (5.5) | .66 |
| | Cerebrovascular disease | 47 (2.5) | 19 (3.8) | 28 (2.1) | 128 (6.0) | .001 |
| | Chronic kidney disease | 38 (2.0) | 13 (2.6) | 25 (1.8) | 68 (3.2) | .02 |
| | Tumor | 32 (1.7) | 13 (2.6) | 19 (1.4) | 55 (2.6) | .06 |
| | Tracheitis | 30 (1.6) | 13 (2.6) | 17 (1.3) | 48 (2.3) | .14 |
| | Chronic obstructive pulmonary disease | 16 (0.9) | 7 (1.4) | 9 (0.7) | 35 (1.6) | .03 |
| | Length of hospital stay, median (IQR), d | 14 (9–20) | 15 (10–23) | 14 (9–20) | 14 (9–20) | .60 |
| | Intensive care unit admission | 36 (1.9) | 30 (5.9) | 6 (0.4) | 72 (3.4) | .005 |
| | Oxygen therapy | 1341 (71.9) | 447 (88.5) | 894 (65.8) | 1559 (73.4) | .30 |
| | Mechanical ventilation | 14 (0.8) | 13 (2.6) | 1 (0.1) | 33 (1.6) | .02 |

Abbreviation: NA, not applicable.

* Statistical tests were calculated with the Pearson χ² test unless otherwise noted.

b Calculated with Mann-Whitney U test.

c Calculated with Fisher exact test.
common symptoms in the new-onset symptoms group were fatigue, anxiety, chest tightness, cough, and expectoration (Figure 2B). Of note, the proportion of dyspnea was much higher in the symptoms persist group than the new-onset symptoms group (30 patients [13.4%] vs 7 patients [4.8%]).

**Factors Associated with Risk of Symptom Persistence at 2-Year Follow-up**

On univariable analysis, age, sex, disease severity, and ICU admission were associated with symptom persistence, compared with the symptom relief group. In a multivariable analysis, only ICU admission (odds ratio [OR], 2.69; 95% CI, 1.02-7.06; \( P = .04 \)) was associated with a higher risk of symptom persistence at 2 years (eTable 10 in the Supplement). Coexisting cerebrovascular diseases (OR, 3.23; 95% CI, 1.36-7.69; \( P = .008 \)) were associated with new-onset symptoms, compared with the no symptoms group (eTable 11 in the Supplement). Of note, of 47 patients with coexisting cerebrovascular diseases, 43 (91.5%) had more than 2 coexisting diseases, which was much higher than the proportion among patients with coexisting diseases other than cerebrovascular diseases (285 of 745 patients [38.3%]). In patients who had more than 2 symptoms at 2-year follow-up, age (OR, 1.03; 95% CI, 1.01-1.04; \( P < .001 \)) and chronic liver disease (OR, 2.22; 95% CI, 1.19-4.14; \( P = .01 \)) were independently associated with the risk of symptom persistence (eTable 12 in the Supplement).

**CAT Scores at 2-Year Follow-up**

Previously, CAT has been used to assess symptom burden of patients with COVID-19.\(^9,15\) At 2 years after hospital discharge, the median (IQR) CAT score was 2 (0-4) in the total cohort, and the severe...
disease group had a significantly higher median (IQR) CAT score compared with the nonsevere group (3 [0-5] vs 2 [0-4]) (Figure 3A). A total of 116 patients (6.2%) had CAT total scores of 10 or higher, and the proportion was higher in the severe disease group than in the nonsevere disease group (severe vs nonsevere, 48 patients [9.5%] vs 68 patients [5.0%]) (Figure 3B). Patients who had CAT total scores of 10 or more were older, had a higher proportion of severe disease, more coexisting disorders, longer length of hospital stays, and a greater use of oxygen therapy than patients with lower CAT scores (eTable 13 in the Supplement).

The CAT item scores are shown in Figure 3C, which suggest that more patients tended to have sleep disorder and poor energy state than other symptoms. After multivariable adjustment, age (OR, 1.04; 95% CI, 1.03-1.06; \( P < .001 \)), ICU admission (OR, 2.83; 95% CI, 1.21-6.66; \( P = .02 \)), and chronic liver disease (OR, 2.18; 95% CI, 1.10-4.33; \( P = .03 \)) were found to be factors independently associated with the risk of CAT scores of 10 or higher at 2-year follow-up (Figure 3D and eTable 14 in the Supplement). Higher CAT item scores regarding breathlessness, sleep, and energy were found in those with chronic liver disease (eFigure 2 in the Supplement).

**Discussion**

In this cohort study, at 2 years after hospital discharge, 370 patients (19.8%) still had symptoms, including 224 (12.0%) with persistent symptoms and 146 (7.8%) reporting new-onset or worsening symptoms from a reported level of mild at year 1. The most common symptoms were fatigue, chest tightness, anxiety, dyspnea, and myalgia. Most symptoms resolved over time, except for dyspnea, but at 1 year it was already at a low level. ICU admission was associated with higher risks of symptoms persisting, whereas coexisting cerebrovascular diseases were associated with new-onset symptoms. In total, 116 patients (6.2%) had CAT total scores of at least 10, for whom the factors associated with increased risk included ICU admission during hospital stay or coexisting chronic liver diseases. Taken together, these findings add to our current knowledge of health outcome dynamics of COVID-19.

For 2-year survivors of COVID-19, the most common symptom was fatigue, which decreased from 26.9% at 1-year follow-up to 10.3% at 2-year follow-up. There was a general decreasing trend for this symptom, which was confirmed in another study. The post–COVID-19 fatigue is similar to postinfectious fatigue syndromes following other well-documented infectious diseases, including SARS-CoV-1 (the cause of severe acute respiratory disease) and Ebolavirus, among others. For SARS-CoV-1, postinfectious fatigue could last as long as 4 years.

Most patients with dyspnea at 1-year follow-up still had this symptom at 2-year follow-up. Previously, Bellan et al observed that the proportion of patients with COVID-19 with dyspnea increased significantly over time, despite a stable diffusing capacity for carbon monoxide. In another prospective, longitudinal study of patients with SARS-CoV-1, at 24 months after disease onset,

**Table 2. Symptom Dynamics of COVID-19 Survivors According to Disease Severity**

| Categories               | No. of symptoms | Patients, No. (%) | \( P \) value, severe vs nonsevere disease |
|--------------------------|-----------------|-------------------|-------------------------------------------|
|                          | 1-y follow-up   | 2-y follow-up     | Enrolled patients | Severe disease | Nonsevere disease |
| Total                    | NA              | NA                | 1864 (100.0) | 505 (100.0) | 1359 (100.0) | NA |
| Symptoms persist\( a \) | ≥1              | ≥1                | 224 (12.0) | 89 (17.6) | 135 (9.9) | <.001 |
| Symptom relief\( b \)   | ≥1              | 0                 | 582 (31.2) | 175 (34.7) | 407 (29.9) | .05 |
| New-onset symptoms\( c \) | 0              | ≥1                | 146 (7.8) | 34 (6.7) | 112 (8.2) | .28 |
| No symptoms\( d \)      | 0               | 0                 | 912 (48.9) | 207 (41.0) | 705 (51.9) | <.001 |

Abbreviation: NA, not applicable.

\( a \) Refers to patients with at least 1 symptom at both 1-year and 2-year follow-up.

\( b \) Refers to patients with at least 1 symptom at 1-year follow-up but without any symptoms at 2-year follow-up.

\( c \) Refers to patients without any symptoms at 1-year follow-up, but reported at least 1 symptom at 2-year follow-up, including patients who had a symptom that was reported as a mild problem at year 1, but at 2-year follow-up was reported as moderate or severe problem.

\( d \) Refers to patients with no symptoms at any follow-up.
persistent impairment of 6-m walk distance was observed, and it contributed to the reduced quality of life. The current study identified chronic liver disease as a factor associated with the risk of symptom persistence, as well as CAT scores of 10 or higher. Previously, a large multicenter study identified specific subgroups of patients with chronic liver disease who had higher mortality with COVID-19. In the current study, patients with chronic liver disease had higher item scores regarding

Figure 3. Total and Item Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) Scores in Patients at 2-Year Follow-up

A. Total CAT score

B. CAT score <10 vs ≥10

C. Responses to individual CAT items

D. Factors associated with risk of CAT total score ≥10

Factors OR (95% CI)  P value
Age, per 1-y 1.04 (1.03-1.06)  <.001
Male sex 1.02 (0.69-1.50)  .92
Severity (vs nonsevere) 1.41 (0.93-2.13)  .11
ICU admission 2.83 (1.21-6.66)  .02
Chronic liver diseases 2.18 (1.10-4.33)  .03

A. Total CAT score at 2 years after patient discharge; lines within bars denote means, and error bars denote 95% CIs. B. Percentage of patients with CAT score 10 or higher and less than 10. C. Histogram of responses to individual CAT items; confidence refers to a CAT item concerning confidence leaving the home. D. Factors associated with risk of CAT total scores 10 or higher. ADL indicates activities of daily living; OR, odds ratio.
breathlessness, sleep, and energy, which indicates that coexisting chronic liver disease may be associated with both pulmonary-specific and nonspecific CAT subitems.

The presence of patients with new-onset symptoms raises important questions about causality and the mechanisms that could result in the development of symptoms at least 1 year after the acute illness. Our definition of new-onset symptoms included patients who had a symptom that was reported as mild at year 1 but moderate or severe at year 2. This could include patients who initially had a mild symptom that worsened over time because of a progressive element to their disease. Coexisting cerebrovascular diseases were associated with increased risk of new-onset symptoms, and it has been reported that coexisting cerebrovascular disease during hospitalization was 1 of the top 3 factors associated with COVID-19 severity24 and was associated with postacute sequelae of COVID-19.25 We also found that patients with coexisting cerebrovascular disease had more coexisting disorders of other organ systems, which raised the possibility that diseases other than COVID-19 may have been associated with the new-onset symptoms, so it is difficult to determine whether new-onset symptoms were completely attributable to long COVID-19.

Limitations

There are several limitations to our study. The first is common to most studies of COVID-19: the absence of an age-matched and comorbidity-matched control group. It is, therefore, not possible to directly ascribe the patients’ long-term symptoms to the acute illness, particularly for patients who are at an age when comorbidities and their associated symptoms are common and will increase over time. For example in a population study in Australia,9.5% of people surveyed had a modified Medical Research Council dyspnea score of 2 or higher. However, the longitudinal nature of our study showing progressive reduction in symptoms over time following the acute episode suggests an association between the acute event and the persistent symptoms. In terms of limitations that are specific to this study, the enrolled patients were less than half of the eligible population discharged from hospital. Patients lost to follow-up were older than those who continued in the study, which is important because age is an effect modifier of post–COVID-19 symptoms, and older patients had more pre-existing disorders, thus introducing a risk of survivor bias. Although we performed a PSM process, this method is limited to the factors that were measured, and other important unmeasured factors may have been operating, so residual selection bias may have persisted. Second, we used a self-reported symptom questionnaire rather than specific diagnostic tools, predisposing a risk of bias due to patients’ subjectivity, and the number of symptoms involved in our study was small considering that more than 100 potential COVID-19–related symptoms have been reported,27,28 which may introduce bias in that patients are less likely to willingly provide information not on the survey questionnaires.29,30 Third, constantly emerging coronavirus variants have been endemic31 and may have different virulence and long-term sequelae with our findings.

Conclusions

In this longitudinal cohort study that included 1864 hospitalized COVID-19 survivors, the most common symptoms at 2 years after discharge were fatigue, chest tightness, anxiety, dyspnea, and myalgia. Most symptoms resolved, yet dyspnea persisted at a very low level over time. Patients with severe disease during hospitalization, especially ICU admission, had higher risks of symptom persistence and CAT total scores of at least 10. The findings provide valuable information about the dynamic trajectory of long-term health outcomes of COVID-19 survivors.
Open Access: This is an open access article distributed under the terms of the Creative Commons Attribution License. © 2022 Yang X et al. JAMA Network Open.

Corresponding Authors: Li Li, MD, Department of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing 400042, China (dpyyhxili@tmmu.edu.cn); Bin Cao, MD, Department of Pulmonary and Critical Care Medicine, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China (caobin_ben@163.com).

Author Affiliations: Department of Respiratory Medicine, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China (Yang, Hou, Shen, M. Zhang, F. Wang, Kang, Hu, M. Wang, He, G. Cao, Li); Department of Rehabilitation, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China (Shen); Department of Outpatient, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China (K. Zhang); Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China (Liu, Y. Yang); Wuhan Huoshenshan Hospital, Wuhan, China (Liu, G. Cao, Li); Department of Epidemiology, College of Preventive Medicine, Third Military Medical University (Army Medical University), Chongqing, China (Ma); Department of Medical and Research Management, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China (Cheng); Wuhan Taikang Tongji Hospital, Wuhan, China (Cheng, Kang); Department of Trauma Medical Center, Daping Hospital, State Key laboratory of Trauma, Burns, and Combined Injury, Third Military Medical University (Army Medical University), Chongqing, China (Zeng, Jiang); Institute of Infection and Immunology, University of London, London, United Kingdom (Jones); GlaxoSmithKline, Brentford, United Kingdom (Jones); Department of Pulmonary and Critical Care Medicine, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China (B. Cao).

Author Contributions: Dr Li had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Ms Yang, Mr Hou, Ms Shen, Mr M. Zhang, Ms K. Zhang, and Ms F. Wang contributed equally to this work.

Concept and design: Ma, He, G. Cao, Jiang, B. Cao, Li.
Acquisition, analysis, or interpretation of data: Yang, Hou, Shen, M. Zhang, K. Zhang, F. Wang, Liu, Ma, Cheng, Kang, Hu, M. Wang, Zeng, Y. Wang, Jones, Li.
Drafting of the manuscript: Yang, Hou, Shen, M. Zhang, G. Cao, Jiang, Li.
Critical revision of the manuscript for important intellectual content: Yang, K. Zhang, F. Wang, Liu, Ma, Cheng, Kang, Hu, M. Wang, Zeng, Y. Wang, He, G. Cao, Jiang, Jones, B. Cao, Li.
Statistical analysis: Shen, Ma, Zeng.
Obtained funding: Ma, Cheng, Li.
Administrative, technical, or material support: Liu, Y. Wang, He, B. Cao.
Supervision: G. Cao, Li.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported by the National Natural Science Foundation of China (81672287), the Joint Scientific Research Project of the Chongqing Health Commission and the Science and Technology Commission (2020FYXX213), the Outstanding Youth Science Fund of Chongqing (cstc2020jcyjqX0014), Chongqing Talent Fund (CQYJZ2020OS003), Chongqing Special Project for Academicians (cstc2020yszsy-jcyjX0004), and the Science Foundation for Outstanding Young People of the Army Medical University.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES
1. World Health Organization. COVID-19 dashboard. 2020. Accessed May 1, 2022. https://covid19.who.int/
2. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657-663. doi:10.1038/s41586-021-04385-3
3. Telenti A, Arvin A, Corey L, et al. After the pandemic: perspectives on the future trajectory of COVID-19. Nature. 2021;596(7873):495-504. doi:10.1038/s41586-021-03792-w
4. Bek LM, Berentschot JC, Hellemans ME, et al; CO-FLOW Collaboration Group. CO-FLOW: Covid-19 follow-up care paths and long-term outcomes within the Dutch health care system: study protocol of a multicenter prospective cohort study following patients 2 years after hospital discharge. *BMC Health Serv Res*. 2021;21(1):847. doi:10.1186/s12913-021-06813-6

5. Maestre-Muñiz MM, Arias A, Mata-Vázquez E, et al. Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge. *J Clin Med*. 2021;10(13):2945. doi: 10.3390/jcm10132945

6. Huang C, Huang L, Wang Y, et al. 6-Month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220-232. doi:10.1016/S0140-6736(20)32656-8

7. Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. *BMJ*. 2022;376:e068993. doi:10.1136/bmj-2021-068993

8. Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. *JAMA*. 2022;327(6):559-565. doi: 10.1001/jama.2022.0040

9. Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. *Lancet Respir Med*. Published online May 11, 2022. doi:10.1016/S2213-2600(22)00126-6

10. Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores. *BMC Pulm Med*. 2011;11(1):42. doi: 10.1186/1471-2466-11-42

11. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. *Respirology*. 2017;22(3):575-601. doi: 10.1111/resp.13012

12. GlaxoSmithKline. COPD assessment test (CAT). Accessed June 4, 2022. https://www.catestonline.org/

13. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*. 2022;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9

14. Daynes E, Gerlis C, Briggs-Price S, Jones P, Singh S. COPD assessment test for the evaluation of COVID-19 symptoms. *Thorax*. 2021;76(2):185-187. doi:10.1136/thoraxjnl-2020-215916

15. Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. *Trends Mol Med*. 2021;27(9):895-906. doi:10.1016/j.molmed.2021.06.002

16. Epstein L, Wong KK, Kallen AJ, Uyeki TM. Post-Ebola signs and symptoms in U.S. survivors. *N Engl J Med*. 2015;373(25):2484-2486. doi:10.1056/NEJMct1506576

17. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome: a case-controlled study. *BMC Neurol*. 2011;11(1):37. doi:10.1186/1471-2377-11-37

18. Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. *Trends Mol Med*. 2021;27(9):895-906. doi:10.1016/j.molmed.2021.06.002

19. Epstein L, Wong KK, Kallen AJ, Uyeki TM. Post-Ebola signs and symptoms in U.S. survivors. *N Engl J Med*. 2015;373(25):2484-2486. doi:10.1056/NEJMct1506576

20. Lam MHB, Wing YK, Yu MWM, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. *Arch Intern Med*. 2009;169(22):2142-2147. doi:10.1001/archinternmed.2009.384

21. Bellan M, Baricich A, Patruncio F, et al. Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19. *Sci Rep*. 2021;11(1):22666. doi:10.1038/s41598-021-02125-4

22. Ngai JC, Ko FW, Ng SS, To KW, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. *Respirology*. 2010;15(3):543-550. doi:10.1111/j.1440-1843.2010.01720.x

23. Kim D, Adeniji N, Latt N, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study. *Clin Gastroenterol Hepatol*. 2021;19(7):1469-1479.e19. doi:10.1016/j.cgh.2020.09.027

24. Fang X, Li S, Yu H, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. *Aging (Albany NY)*. 2020;12(13):12493-12503. doi:10.18632/aging.103579

25. Novak P, Mukerji SS, Alabisi HS, et al. Multisystem involvement in post-acute sequelae of coronavirus disease 19. *Ann Neurol*. 2022;91(3):367-379. doi:10.1002/ana.26286
26. Poulos LM, Amporn RD, Currow DC, Marks GB, Toelle BG, Reddel HK. Prevalence and burden of breathlessness in Australian adults: the National Breathlessness Survey—a cross-sectional web-based population survey. *Respirology*. 2021;26(8):768-775. doi: 10.1111/resp.14070

27. Mehandru S, Merad M. Pathologic sequelae of long-haul COVID. *Nat Immunol*. 2022;23(2):194-202. doi: 10.1038/s41590-021-01104-y

28. Aiyegbusi OI, Hughes SE, Turner G, et al; TLC Study Group. Symptoms, complications and management of long COVID: a review. *J R Soc Med*. 2021;114(9):428-442. doi: 10.1177/01410768211032850

29. Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding post-acute sequelae of COVID-19. *Front Immunol*. 2021;12:686029. doi: 10.3389/fimmu.2021.686029

30. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and management. *BMJ*. 2021;374:n1648. doi: 10.1136/bmj.n1648

31. Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. *Lancet*. 2022;399(10340):2011-2012. doi: 10.1016/S0140-6736(22)00838-8

SUPPLEMENT.
eTable 1. Symptom Questionnaire
eTable 2. Symptoms During COVID-19 Hospitalization of Enrolled Patients and Those Lost to Follow-up
eTable 3. Characteristics of Enrolled Participants and Those Lost to Follow-up Between 1-Year and 2-Year Follow-up
eTable 4. One-Year Sequelae of Enrolled Participants and Those Lost to Follow-up Between 1-Year and 2-Year Follow-up
eFigure 1. Percentage of Patients Presenting With Different Numbers of Symptoms at 1-Year Follow-up and 2-Year Follow-up
eTable 5. Dynamic Changes of Symptoms During 2-Year Follow-up According to Disease Severity
eTable 6. Characteristics of the Propensity Score-Matched Population
eTable 7. Symptoms at 1-Year Follow-up and 2-Year Follow-up in Overall and Propensity Score-Matched Populations
eTable 8. Symptoms at 2-Year Follow-up in Overall and Propensity Score-Matched Populations According to Disease Severity
eTable 9. Symptom Dynamics of COVID-19 Survivors According to Disease Severity in Propensity Score-Matched Population
eTable 10. Logistic Regression Models to Evaluate the Risk Factors for Symptom Persist vs Relief
eTable 11. Logistic Regression Models to Evaluate the Risk Factors for Symptom New-Onset vs No Sequelae
eTable 12. Logistic Regression Models to Evaluate the Risk Factors for More Than Two Symptoms at 2-Year Follow-up
eTable 13. Patient Characteristics Between Those With CAT Total Scores ≥ 10 and Those < 10
eTable 14. Logistic Regression Models to Evaluate the Risk Factors for CAT Score ≥10
eFigure 2. CAT Item Scores Between Patients With and Without Coexisting Chronic Liver Disease